PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
07-May-2025 Vetter Prioritizes Continuity and Action in its Sustainability Efforts Vetter
07-May-2025 Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML) Priothera
07-May-2025 Beacon Therapeutics announced positive data from Phase II DAWN trial Syncona Limited
07-May-2025 The European Association of Endoscopic Spine Surgery is born to lead medical excellence and surgical innovation in Europe European Association of Endoscopic Spine Surgery
07-May-2025 Theriva Biologics Announces Pricing of $7.5 Million Public Offering Theriva Biologics
07-May-2025 Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients Theriva™ Biologics
07-May-2025 Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis Tiziana Life Sciences
07-May-2025 Fresenius Q1/25: Strong start to 2025 – #FutureFresenius Rejuvenate phase kicked-off with excellent momentum Fresenius
07-May-2025 Viatris Announces Quarterly Dividend Viatris
07-May-2025 Powering the Future of Lupus Treatments Worldwide Clinical Trials
07-May-2025 Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies ICON
07-May-2025 Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025 Novo Nordisk
07-May-2025 Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 Gilead
07-May-2025 Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment Gilead
07-May-2025 ELRIG Announces Keynote Speakers for Drug Discovery 2025 ELRIG
06-May-2025 Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy Xlife Sciences
06-May-2025 ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference ProQR
06-May-2025 Research advances on ‘displacing’ antibiotic resistance gene from bacteria University of Birmingham
06-May-2025 Health Secretary Tours Site of Scotland’s Largest Vaccine Producer Valneva Scotland
06-May-2025 Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier Microbiotica